Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Skin and Connective Tissue Diseases

Digestive System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Stomach Neoplasms

Prostatic Neoplasms

Carcinoma

Carcinoma, Squamous Cell

Lung Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Adenocarcinoma

Triple Negative Breast Neoplasms

Carcinoma, Renal Cell

Esophageal Squamous Cell Carcinoma

Carcinoma, Transitional Cell

Squamous Cell Carcinoma of Head and Neck

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Neoplasms, Squamous Cell

Breast Diseases

Skin Diseases

Head and Neck Neoplasms

Esophageal Neoplasms

Esophageal Diseases

Stomach Cancer

Small Cell Lung Cancer

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Transitional Cell Carcinoma

Esophageal Cancer

All Drugs and Chemicals

Antineoplastic Agents

Antibodies

Paclitaxel

Gemcitabine

Pembrolizumab

Albumin-Bound Paclitaxel

Immunoglobulins

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

GB1275 Monotherapy dose escalation: Oral administration. Twice per day (BID).

GB1275 with pembrolizumab dose escalation and expansion:

GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).

GB1275 with SOC dose escalation:

GB1275 oral administration; twice per day (BID), and nab-paclitaxel and gemcitabine per United States Prescribing Information (USPI)

GB1275 with SOC Basket Cohort in patients with newly diagnosed metastatic pancreatic cancer:

GB1275 oral administration; twice per day (BID) and nab-paclitaxel and gemcitabine per USPI.

GB1275 with pembrolizumab Basket Cohort in patients with MSS colorectal cancer:

GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).

GB1275 with pembrolizumab Basket Cohort in patients with gastric/GEJ cancer, PD-L1 positive:

GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).

GB1275

nab-paclitaxel and gemcitabine

pembrolizumab

This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid Tumors

Note: The Phase 2 portion of the study was not initiated.

Phase 1 - Dose Escalation of 3 different Regimens and Expansion, Phase 2 - Basket Expansion of 3 Cohorts

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors

Time of maximum observed plasma concentration

Area under the plasma concentration-time curve

ORR defined as the proportion of subjects with best overall confirmed response (BOCR) of either a complete response (CR) or partial response (PR) as assessed by the Investigator based on RECIST v1.1

DOR defined as time from date of objective response to first documented date of disease progression or death

TTR defined as time from first dose to first date of objective response

CBR defined as proportion of subjects with confirmed CR, PR, or stable disease (SD) at six months.

PFS defined as time from first dose to first documented date of disease progression or death.

TTP defined as time from first dose to first documented date of disease progression.

OS defined as time from first dose to date of death.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma	NCT04060342	Pancreatic Aden... Esophageal Aden... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Triple Negative... Castration-resi... Microsatellite ... Non-small Cell ... Small-cell Lung... Head and Neck S... Urothelial Carc... Renal Cell Carc... Hepatocellular ...	GB1275 nab-paclitaxel ... pembrolizumab	18 Years -	Gossamer Bio Inc.
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma	NCT04060342	Pancreatic Aden... Esophageal Aden... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Triple Negative... Castration-resi... Microsatellite ... Non-small Cell ... Small-cell Lung... Head and Neck S... Urothelial Carc... Renal Cell Carc... Hepatocellular ...	GB1275 nab-paclitaxel ... pembrolizumab	18 Years -	Gossamer Bio Inc.

Spots Global Cancer Trial Database for gb1275

Every month we try and update this database with for gb1275 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for gb1275

Every month we try and update this database with for gb1275 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for gb1275 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.